You are hereNoida
At UnitedHealth Group, their mission is to help people live healthier lives. To achieve this goal, they are focused on building a modern, adaptable, innovative and inclusive system of health care services.
Their scale and potential to improve health makes them one of the most visible stewards of America’s vast health care system. Entrusted with both important resources and responsibilities, they are involved on a daily basis in decision-making that has life-changing consequences for millions of Americans.
RSSDI Annual Scientific Meetings provide a wonderful opportunity to all of us, to meet and interact with each other and share our research, knowledge and clinical experience in all facets of diabetes care. RSSDI-2013 will be yet another enriching scientific experience, where we shall strive hard to meet the expectations of clinicians and researchers alike.
The Jaypee Group of Companies has consistently displayed full awareness of its social responsibilities through the Jaiprakash Sewa Sansthan (JSS), a ‘not for profit’ Trust. The Group believes that Education is the cornerstone to economic development and which alone can assist build India into a developed nation.
With the thought of using technology and management effectively, thevisionary founder of the JSS, Shri Jaiprakash Gaur set up 3 technical institutes of higher education to host the best of faculty, students and educational infrastructure to ensure creation, generation, dissemination and application of knowledge to mould the world leaders of tomorrow.
Olefia Biopharma Limited is one of most dynamic organizations, involved in manufacturing pharmaceutical formulations marketing its products in India as well as worldwide. Olefia has been pursuing its primary mission to provide quality healthcare to ailing millions across the globe at an affordable cost. “Where there is will there is way” is the ground principle for us and based on this principle. Olefia is working today as diverse company of the future. We can make a difference by taking up a cause that we are passionate about.
New Horizons in Pharmacy Education @ Apeejay Stya University, Gurgaon | Admissions open for M.Pharm, Ph.D, MBA
The School of Pharmaceutical Sciences, Apeejay Stya University offers highly advanced and internationally aligned post-graduate courses in Pharmacy Education. The following courses are on offer:
Work as PROFESSIONAL SERVICE REPRESENTATIVES, AREA MANAGER in Karnataka Antibiotics & Pharmaceuticals Ltd.
Karnataka Antibiotics & Pharmaceuticals Ltd., (KAPL) Bangalore is a Government Enterprise. From a modest beginning in 1984, KAPL has grown from strength to strength in the areas of manufacturing and marketing of various life saving and essential drugs. With an ISO accredition from KPMG, Netherlands, KAPL is recognised for its total commitment to quality and services in domestic and international markets. On profit from inception, KAPL facilities are approved by many international clients.
We are an established Pharmaceutical Company having a committed team of 825 professionals across the country. Having created a position for ourselves among Top 35 Pharmaceutical Companies prescription wise, we are further strengthening our presence in potential specialty areas -Cardiovascular and Anti-Diabetic Segments. For our expansion programme we require:
Post: Zonal Sales Manager, Regional Sales Manager
*1Akanksha baranwal, 2Akanksha Sharma, 3Anamika singh
1,3Department of pharmacology
2Department of clinical research
Noida Institute of Engineering and Technology
The purpose of this review is to provide a basic understanding of the important relationship between microvascular remodelling, angiogenesis and hypertension, that is, provide an overview of recent experimental and clinical evidence from anti-hypertensive and pro- and anti-angiogenic therapy with respect to hypertension and microvascular structure. Microvascular rarefaction, that is, a loss of terminal arterioles and capillaries, is found in most forms of human and experimental arterial hypertension. This further increases peripheral resistance, and aggravates hypertension and hypertension-induced target organ damage. In some cases with a genetic predisposition, hypertension is preceded by a loss of microvessels. Therefore, new therapies aimed at reversing microvascular rarefaction potentially represent candidate treatments of hypertension. The microvasculature is formed by the continuous balance between de novo angiogenesis and microvascular regression. Imbalanced angiogenesis, in addition to functional shut-off of blood flow, contributes to microvascular rarefaction. Numerous clinical trials assessing anti-angiogenic agents in cancer patients show that this therapy leads to microvascular rarefaction and causes or aggravates hypertension. The development of specific pro-angiogenic treatment to correct hypertension or ischaemic disorders, however, it is still in its infancy. On the other hand, long-term treatment by classic anti-hypertensive therapies that present vasodilator activity can correct for hypertension-associated rarefaction in man.
The National Institute of Biologicals, an autonomous Institute under the Ministry of Health & Family Welfare, Government of India, is a premier Scientific Organization and a Centre of Excellence to ensure quality of vaccines and biologicals in the country.
Applications are invited for the following posts on direct recruitment basis:
Post: Jr. Scientist
Anamika singh*1, Neha Singh2
1M.Pharm (Department of Pharmacology)
2M.Pharm (Department of Pharmaceutics)
Noida Institute of Engineering and Technology.
Tuberculosis is a leading killer of young adults worldwide and the global scourge of multi-drug resistant tuberculosis is reaching epidemic proportions. It is endemic in most developing countries and resurgent in developed and developing countries with high rates of human immunodeficiency virus infection. This article reviews the current situation in terms of drug delivery approaches for tuberculosis chemotherapy. A number of novel implant-, microparticulate-, and various other carrier-based drug delivery systems incorporating the principal anti-tuberculosis agents have been fabricated that either target the site of tuberculosis infection or reduce the dosing frequency with the aim of improving patient outcomes. These developments in drug delivery represent attractive options with significant merit, however, there is a requisite to manufacture an oral system, which directly addresses issues of unacceptable rifampicin bioavailability in fixed-dose combinations. This is fostered by the need to deliver medications to patients more efficiently and with fewer side effects, especially in developing countries. The fabrication of a polymeric once-daily oral multiparticulate fixed-dose combination of the principal anti-tuberculosis drugs, which attains segregated delivery of rifampicin and isoniazid for improved rifampicin bioavailability, could be a step in the right direction in addressing issues of treatment failure due to patient non-compliance.